Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Greenleaf Trust

Greenleaf Trust lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,548 shares of the biopharmaceutical company’s stock after acquiring an additional 1,351 shares during the period. Greenleaf Trust’s holdings in Gilead Sciences were worth $2,452,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in GILD. nVerses Capital LLC acquired a new position in Gilead Sciences during the third quarter worth approximately $25,000. Valued Wealth Advisors LLC increased its position in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the period. Decker Retirement Planning Inc. acquired a new position in Gilead Sciences during the fourth quarter worth approximately $29,000. Crews Bank & Trust acquired a new position in Gilead Sciences during the fourth quarter worth approximately $31,000. Finally, Quarry LP acquired a new position in Gilead Sciences during the second quarter worth approximately $43,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on GILD shares. UBS Group lifted their price target on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Robert W. Baird lifted their target price on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Finally, Wells Fargo & Company lifted their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $98.39.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock valued at $42,130,461 over the last three months. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Stock Up 0.3 %

GILD opened at $97.20 on Monday. The business’s fifty day moving average is $92.42 and its two-hundred day moving average is $85.87. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The company has a market cap of $121.14 billion, a price-to-earnings ratio of 1,080.00, a PEG ratio of 1.34 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.29 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.